RESUMO
We report an epidemic of parvovirus B19 infections in Denmark during the first quarter of 2024, with a peak incidence 3.5 times higher than during the most recent epidemic in 2017. In total, 20.1% (130/648) of laboratory-confirmed cases were pregnant. Severe adverse outcomes were observed among 12.3% (16/130) of pregnant people and included foetal anaemia, foetal hydrops and miscarriage. Parvovirus B19 infection is not systematically monitored, but a national laboratory-based surveillance system is currently being established in Denmark.
Assuntos
Infecções por Parvoviridae , Parvovirus B19 Humano , Complicações Infecciosas na Gravidez , Humanos , Feminino , Gravidez , Dinamarca/epidemiologia , Parvovirus B19 Humano/isolamento & purificação , Complicações Infecciosas na Gravidez/epidemiologia , Complicações Infecciosas na Gravidez/diagnóstico , Complicações Infecciosas na Gravidez/virologia , Adulto , Incidência , Infecções por Parvoviridae/epidemiologia , Infecções por Parvoviridae/diagnóstico , Epidemias , Hidropisia Fetal/epidemiologia , Hidropisia Fetal/virologia , Índice de Gravidade de Doença , Adulto Jovem , Eritema Infeccioso/epidemiologia , Eritema Infeccioso/diagnóstico , Adolescente , Aborto Espontâneo/epidemiologia , Aborto Espontâneo/virologia , Vigilância da PopulaçãoRESUMO
We report a surge of patients, especially children and adolescents, with respiratory disease caused by Mycoplasma pneumoniae in Denmark since October 2023. While the surge has reached an epidemic level, no impact on hospital capacity has been observed; only 14% (446/3,195) of cases, primarily adults, required hospitalisation. Macrolide resistance was detected in less than 2% of samples tested. Timely monitoring of hospitalisations linked to M. pneumoniae infections has been established to inform the healthcare system, decisionmakers and the public.
